Business
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
Reports steady progress towards start of Phase 3 trialHERZLIYA, ISRAEL / ACCESSWIRE / January 4, 2021 / PainReform Ltd. (NasdaqCM:PRFX) ("PainReform" or the
About this update from Prf Technologies Ltd.
[{"type":"text","content":"Reports steady progress towards start of Phase 3 trialHERZLIYA, ISRAEL / ACCESSWIRE / January 4, 2021 / PainReform Ltd. (NasdaqCM:PRFX) (\"PainReform\" or the \"Company\"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established pain drugs, today announced the appointment of Lotus Clinical Research (\"LCR\") as its clinical research organization (\"CRO\") to conduct the Company's upcoming Phase 3 trial of PRF-110 in patients undergoing bunionectomy and hernia repair operations and the entering into an agreement with Lotus covering such trials.LCR is a specialty analgesic focused CRO with a proven track record of conducting successful, full-service analgesic studies from startup through all phases of analgesic clinical trials. LCR has its own clinical sites that support all phases of clinical trials for novel analgesics and specifically in the area of post-operative pain, including bunion and hernia. LCR has developed an acute pain model that offers numerous advantages over traditional models, providing clients with active engagement and recruitment of study subjects, on-site accessibility of surgical and recovery services, and lowered project costs throughout a study's lifecycle. LCR has been involved in approximately 350 pain trials that led to over ten approvals.PainReform has been working with LCR's Chief Scientific Officer, Dr. Neil Singla, for over two years in planning these trials. Dr. Singla is a nationally recognized key opinion leader in analgesic protocol design and implementation. He has published extensively and is a frequent lecturer for physicians, pharmaceutical companies, and medical research institutes throughout the country. For the past several years, the main focus of Dr. Singla's academic endeavors has been to analyze and understand how the inherent variability in subjective endpoint clinical trials can be minimized. He has developed novel techniques for patient education designed to minimize variability, reduce placebo response, and increase effect size.Ilan Hadar, CEO of PainReform, noted, \"We are delighted to announce the appointment of LCR as our CRO, which marks another important milestone as we prepare to commence our pivotal Phase 3 trials for PRF-110. LCR brings extensive and unique expertise in conducting analgesic studies, which we believe will help ensure a ...